IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDEAYA (NASDAQ: IDYA) announced first‑patient‑in for a Phase 1 dose‑escalation trial of IDE574, a potential first‑in‑class oral dual inhibitor of KAT6 and KAT7, on April 6, 2026. The trial will evaluate safety, pharmacokinetics, and monotherapy efficacy in solid tumors including breast, prostate, colorectal, and lung cancer.
IDE574 shows single‑digit to low‑teen nanomolar cellular potency, ~350‑to‑2,000x selectivity versus KAT5/KAT8, and superior preclinical monotherapy durability versus KAT6 selective inhibitors; a preclinical profile will be presented at AACR 2026.
IDEAYA (NASDAQ: IDYA) announced first-patient-in (FPI) for a Phase 1 combination study of IDE849 (DLL3-targeting TOP1 ADC) plus IDE161 (PARG inhibitor) in DLL3-upregulated solid tumors, including SCLC, NETs, NECs, and melanoma.
The ongoing global IDE849 Phase 1 program is evaluating 3.5 mg/kg IV Q3W in dose escalation and a 2.4 mg/kg IV Q3W expansion cohort where multiple RECIST v1.1 partial responses were observed; a clinical data update is planned for H2 2026.
IDEAYA Biosciences (NASDAQ: IDYA) announced inducement grants on March 26, 2026 of non-qualified stock options totaling 49,000 shares to two newly hired employees under the 2023 Inducement Plan.
The options carry an exercise price of $32.09 (closing price on grant date), a 10-year term, and vest over four years (25% after one year, then monthly over three years), subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) announced investor events and updated timing guidance for topline results from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma. The company projects a database lock in the first half of April, followed by topline data analysis and a live investor webcast.
Management will host live webcasts and fireside chats at Bank of America Merrill Lynch (May 12, 2026) and Stifel Targeted Oncology Virtual Forum (May 19, 2026); replays will be available for 30 days and preregistration will be provided on IDEAYA's investor events page.
IDEAYA Biosciences (NASDAQ: IDYA) announced abstracts for three poster presentations at AACR Annual Meeting, April 17-22, 2026 in San Diego. Presentations cover preclinical data for IDE034 (PTK7/B7-H3 TOP1 bispecific ADC), IDE574 (KAT6/7 inhibitor) and IDE892 (PRMT5 inhibitor).
Each program is in Phase 1 clinical study evaluating safety, tolerability, PK and efficacy across large solid tumors. Poster details include dates, session titles, poster numbers and availability on the company website after the meeting.
IDEAYA (NASDAQ: IDYA) announced first-patient-in for its Phase 1 trial of IDE892, an investigational PRMT5 inhibitor for MTAP-deleted solid tumors. IDE892 shows ~1,400-fold selective binding to MTA-PRMT5, single-digit nanomolar potency, >50-fold potency differential, and pico-molar SmB-SDMA inhibition with >100-fold selectivity. The trial will test monotherapy and a planned combination FPI with IDE397 in mid-2026. IDEAYA targets a CDKN2A development candidate nomination in H2 2026 and an IND in H1 2027. The company will deprioritize Trodelvy combinations and conclude enrollment in those trials.
Biocytogen announced that partner IDEAYA (Nasdaq: IDYA) dosed the first patient in the Phase 1 trial of IDE034, a first-in-class B7H3/PTK7 bispecific TOP1 ADC.
First dosing triggers a $5 million milestone payment to Biocytogen under the companies' July 2024 license agreement. The Phase 1 study will evaluate safety, tolerability, and PK, with planned combination testing including IDEAYA's oral PARG inhibitor IDE161.
IDEAYA Biosciences (NASDAQ: IDYA) announced on February 26, 2026 that its Compensation Committee granted non-qualified stock options to purchase 346,200 shares to three newly hired employees as inducement awards under the 2023 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4).
The options carry an exercise price of $31.90 (closing price on grant date), a 10-year term, and vest over four years (25% at year one, then monthly over three years), subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) announced first‑patient‑in for a Phase 1 dose escalation/expansion trial of IDE034, a B7H3/PTK7 bispecific TOP1 ADC intended for monotherapy and combinations with DDR agents such as IDE161. Dosing of the first patient triggers a $5.0 million milestone payment to Biocytogen.
IDE034 is designed to internalize only when both antigens are co‑expressed, estimated at ~30–40% in select solid tumors, and has shown preclinical monotherapy activity and synergy with IDE161.
IDEAYA Biosciences (Nasdaq: IDYA) appointed Dr. Theodora (Theo) Ross as Chief Development Officer effective Feb 23, 2026.
Dr. Ross will lead early clinical development and long-term R&D strategy, bringing over 30 years of oncology experience and experience advancing five early clinical programs and supporting a $10 billion acquisition.